Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 11,501–11,600 of 15,747
Intrinsically Selective Nanoplatforms for Precision Therapy and Monitoring
Brownsberger, A., Kudary, C., Williams, H. H., Wei, S., Latorre, P., Eastland, R., Sayani, O., Lyu, J., Davey, R., Hopkins, V., et al. (2026) · Journal of Nanotheranostics · doi:10.3390/jnt7020012 · Cited by 2
“Their success has been exemplified by recent clinical applications, including mRNA vaccines for COVID-19 and emerging cancer immunotherapies [64,65].”
Baldolli, A., Fournier, A. L., Verdon, R., & Michon, J. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.010 · Cited by 2
Heo, C.-K., Lim, W.-H., Moon, K.-B., Yang, J.-Y., Kim, S. J., Kim, H., Kim, D.-J., & Cho, E. (2024) · Vaccines · doi:10.3390/vaccines12060676 · Cited by 2
Antibody Recognition of Cancer Cells via Glycan Surface Engineering
Szponarski, M., & Gademann, K. (2022) · ChemBioChem · doi:10.1002/cbic.202200125 · Cited by 2
(2022) · Przeglad Epidemiologiczny · doi:10.32394/75.28 · Cited by 2
Opinion: A serious issue with the standardization of the adenovirus-based COVID-19 vaccines?
Arand, M. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03126-9 · Cited by 1
Choi, J., Carroll, A., Nguyen, V. H., Michta, M., Zhang, X. Q., Lim, Y., & Chung, R. T. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70733 · Cited by 4
The Behavioral Immune System and Vaccination Intentions During the Coronavirus PandemicPreprint
Karlsson, L. C., Soveri, A., Lewandowsky, S., et al. (2021) · doi:10.31234/osf.io/r8uaz · Cited by 2
Self, W. H., Stewart, T. G., Wheeler, A. P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-227796/v1 · Cited by 2
Shostak, Y., Kramer, M. R., Edni, O., Bendersky, A. G., Shafran, N., Bakal, I., Heching, M., Rosengarten, D., Shitenberg, D., Amor, S. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11040799 · Cited by 2
“Standard regimens of COVID-19 mRNA vaccines are highly immunogenic in immunocompetent individuals [5,6].”
BackgroundChiba, S., & Shinohara, K. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.07.004 · Cited by 2
Kim, Y. G., Kim, M. H., Chun, E. M., & Cho, D. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070671 · Cited by 3
“The effectiveness of mRNA vaccines against COVID-19 is well documented [4,5].”
BackgroundAcceptance of COVID 19 Vaccine in India
Khan, A. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.37.006044 · Cited by 2
“Therefore, a safe and effective prophylactic vaccine is urgently needed to contain the pandemic, which has had devastating medical, economic, and social repercussions [8].”
BackgroundSchwendinger, F., Boeck, H. T., Infanger, D., Faulhaber, M., Tegtbur, U., & Schmidt‐Trucksäss, A. (2022) · medRxiv · doi:10.1101/2022.01.01.21268576 · Cited by 2
A novel Rift Valley fever vaccine
Bronder, S., & Sester, M. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00134-2 · Cited by 2
Ren, P., Peng, L., Fang, Z., Suzuki, K., Renauer, P. A., Lin, Q., Bai, M., Yang, L., Li, T., Clark, P. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.17.484817 · Cited by 2
Bae, S., & Myoung, J. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504015 · Cited by 3
“The development of mRNA vaccines (Baden et al., 2021; Corbett et al., 2020; Goel et al., 2021; Jackson et al., Published online: July 21, 2025 2020; Polack et al., 2020; Thomas et al., 2021), in particular, represented a significant scientific achievement, providing high levels of protection…”
Nicolas, A., Sannier, G., Dubé, M., Nayrac, M., Painter, M. M., Goel, R. R., Laporte, M., Medjahed, H., Williams, J. C., Brassard, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.03.502672 · Cited by 2
Tavazzi, E., Porta, G. D., della Cuna, F. S. R., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104120 · Cited by 2
“(9, 22) The associated adverse effects are generally minor (injection-site pain and short-lived febrile symptom), while severe adverse events are rare.(9) Nevertheless, because immunocompromised patients and those on immunomodulators were excluded from the original randomized controlled trials, there is the need for c…”
BackgroundMethodResultInfluentialImpact of SARS-CoV-2 Vaccines on Covid-19 Incidence and Mortality in the United StatesPreprint
Fang, F., Clemens, J. D., Zhang, Z., et al. (2021) · medRxiv · doi:10.1101/2021.11.16.21266360 · Cited by 2
Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort studyPreprint
Andersson, N. W., Thiesson, E. M., Hansen, J. V., & Hviid, A. P. (2023) · medRxiv · doi:10.1101/2023.01.21.23284855 · Cited by 2
Quintero-Barbosa, J. S., Song, Y., Mehl, F., Mathur, S., Livingston, L., Shen, X. S., Montefiori, D. C., Tan, J., & Zeichner, S. L. (2025) · Vaccines · doi:10.3390/vaccines14010014 · Cited by 2
Al‐Janabi, A., Ra, A., Littlewood, Z., Foulkes, A., Hunter, H. J. A., Chinoy, H., Moriarty, C. A., Hyrich, K. L., Limdi, J. K., Yiu, Z. Z. N., et al. (2022) · British Journal of Dermatology · doi:10.1093/bjd/ljac109 · Cited by 3
Yi, L., Zhang, Z., Tian, H., Li, Y., Yao, W., Xie, G., & Li, W. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102809 · Cited by 3
Watson, M. E., Inagaki, K., & Weinberg, J. B. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-21-000011 · Cited by 3
Pehlivan, U. A., & Torun, M. (2022) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20229811 · Cited by 2
Discovery and development of COVID-19 vaccines and therapeutics: nonclinical perspectives
Khan, N. A., Sathish, J. G., & Rohde, C. M. (2024) · The Journal of Toxicological Sciences · doi:10.2131/jts.49.79 · Cited by 3
Vaccines and Oncolytic Virus for the Treatment of Lung Cancer
Dhar, A. K., Palei, N. N., & Kandula, D. R. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_12 · Cited by 3
Vaccination Against COVID-19: Emerging Issues and Future Prospects
Onischenko, G. G., Sizikova, T. E., Lebedev, V. N., & Borisevich, S. V. (2021) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1672 · Cited by 4
Chang, Z. W., Goh, Y. S., Rouers, A., Fong, S., Tay, M. Z., Chavatte, J., Hor, P. X., Loh, C. Y., Huang, Y., Tan, Y. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1206016 · Cited by 2
“Initial trials conducted with healthy individuals demonstrated the induction of humoral and cellular responses by the mRNA-based vaccines BNT162b2 and mRNA-1273 (2, 3).”
BackgroundComparative Effectiveness of the SARS-CoV-2 Vaccines During Delta Dominance
Islam, N., Griffin, D. O., Jarvis, M. S., & Cohen, K. (2022) · Heliyon · doi:10.1016/j.heliyon.2023.e16006 · Cited by 2
“COV2 ⋅ S/J & J/Janssen) vaccines, demonstrated robust efficacy in both clinical trials and in studies looking at real-world efficacy [1 – 3].”
Nanteza, M. B., Nanyonjo, G., Kyakuwa, N., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312377 · Cited by 2
Megna, R. (2021) · Health Policy · doi:10.1016/j.healthpol.2021.09.008 · Cited by 3
Mateyka, L. M., Strobl, P. M., Jarosch, S., Scheu, S. J. C., Busch, D. H., & D’Ippolito, E. (2022) · Vaccines · doi:10.3390/vaccines10101617 · Cited by 2
The impact of COVID-19 on liver transplantation programs in Austria
Hartl, L., Tatscher, E., Weiß, M., Balcar, L., Straßl, R. P., Jachs, M., Mandorfer, M., Soliman, T., Stadlbauer, V., Schemmer, P., et al. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02105-z · Cited by 2
Sweet syndrome after the first dose of SARS‐CoV ‐2 vaccine ( Pfizer‐BioNTech )
Kim, M. J., Kim, J. W., & Na, J. (2022) · Dermatologic Therapy · doi:10.1111/dth.15915 · Cited by 2
“Before authorization, clinical trials had reported the short-term safety and adverse events after administration of the primary series.(1) However, real-world data revealed unexpected various cutaneous manifestations.”
BackgroundKhatri, J., Tahboub, I. N., Anwar, K., Masoudi, M., Graffeo, V. A., & Jamil, M. O. (2024) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096241231645 · Cited by 3
“6,7 It has significantly helped to fight the COVID-19 pandemic.”
BackgroundLazar, R., Oprean, C. M., Badau, L. M., Miron, G., Draganescu, L., Torok, T., Coroian, I., Sabău, D., Iliescu, A., Tamas, L., et al. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2595 · Cited by 2
Corrao, G., Franchi, M., & Mancia, G. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1002910 · Cited by 3
BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
Beccia, F., Regazzi, L., Marziali, E., Beccia, V., Pascucci, D., Mores, N., Vetrugno, G., & Laurenti, P. (2023) · Vaccines · doi:10.3390/vaccines11020477 · Cited by 2
“The data collected showed a safety profile qualitatively similar to that expected on the basis of the results from the two main safety studies by Polack and colleagues and the periodic safety report produced by the Italian pharmacovigilance agency AIFA and the European Medicine Agency—EMA [42,53].”
Thi, H., He, S. Y., Alexandrou, E., & Frost, S. A. (2022) · Nurse Researcher · doi:10.7748/nr.2022.e1816 · Cited by 3
Tam, J. C. H., Sibayan, A. C., Seow, J., Graham, C., Kurshan, A., Merrick, B., Stanton, R. J., & Doores, K. (2025) · bioRxiv · doi:10.1101/2025.02.12.637095 · Cited by 12
Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review
Forchette, L., Palma, L., Sánchez, C., Gibons, R. M., Stephenson-Moe, C. A., & Behers, B. J. (2025) · Vaccines · doi:10.3390/vaccines13060548 · Cited by 2
“Furthermore, the incidence of serious adverse events was low, while self-limiting side effects of mild-to-moderate pain at the injection site, fatigue, and headache were similar to other viral vaccines, albeit at a 2-month median follow-up [3].”
Opportunities in Therapeutic mRNA Stabilization: Sequence, Structure, Adjuvants and Vectors
Choe, J. A., Burger, J. C., Jones, J. M., Panjla, A., & Murphy, W. L. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202400537 · Cited by 4
Mo, H., Zhou, M.-F., Lao, E. P. L., Chan, K.-K., Lai, O.-N., Ho, M.-I., Wong, K.-W., Ho, K.-M., Sio, K.-T., Fong, K.-L., et al. (2024) · Chinese Medicine · doi:10.1186/s13020-023-00877-8 · Cited by 2
“There are several main types of vaccine platforms, including mRNA, inactivated virus, viral vector and protein subunit [46–49].”
BackgroundJeong, C.-H., Na, Y. J., Kim, T. Y., Lee, S., Kim, J., & Ryou, S.-M. (2025) · Scientific Reports · doi:10.1038/s41598-025-16949-8 · Cited by 4
“Unlike traditional therapies that target viral proteins such as the spike protein (vaccines/antibodies) 20 , main protease (nirmatrelvir) 21 or RNA-dependent RNA polymerase (remdesivir) 22 our approach directly targets conserved functional RNA structures within the viral genome itself.”
Anuforo, A. C., Sandhu, M., Yu, J., et al. (2022) · Clinical Immunology Communications · doi:10.1016/j.clicom.2022.03.002 · Cited by 2
Whitley, C. S., & Mitchell, T. C. (2022) · Journal of Biological Methods · doi:10.14440/jbm.2022.390 · Cited by 2
Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
Dormeshkin, D., Katsin, M., Stegantseva, M. V., Golenchenko, S., Shapira, M. A., Dubovik, S., Lutskovich, D. V., Kavaleuski, A., & Meleshko, A. (2023) · Vaccines · doi:10.3390/vaccines11061014 · Cited by 3
“However, its efficiency is significantly lower than that of the approved mRNA vaccines Comirnaty and Spikevax, raising questions about the worldwide deployment of similar DNA vaccines [59,60].”
BackgroundXiao, C., Liu, X., Liu, P., Xu, X., Yao, C., Li, C., Xiao, Q., Guo, T., Zhang, L., Qian, Y., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100928 · Cited by 5
“73,74 In vivo translation of both mRNA vaccines was verified by western blot analyses (Figure S15B).”
Li, R., Li, Y., Zou, Z., Liu, Y., Li, X., Zhuang, G.-H., Shen, M.-W., & Zhang, L. (2021) · medRxiv · doi:10.1101/2021.06.24.21259370 · Cited by 2
“In response, the US 88 has developed effective vaccines against COVID-19 [17-19].”
BackgroundCOVID-19 Booster Vaccine Equity for Patients With Cancer
Prasad, R. N., Patel, M. I., & Palmer, J. D. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.100939 · Cited by 3
Using an epidemiological lens to evaluate the impacts of COVID-19 in Brazil
Hallal, P. C., & Victora, C. G. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf199 · Cited by 3
(2021) · doi:10.1101/2021.09.07.21262725 · Cited by 2
“Several vaccines have been investigated in large clinical trials and have demonstrated safety and efficacy (2-4): among them, BNT162b2 (Pfizer-BioNTech; mRNA), mRNA-1273 (Moderna; mRNA), and ChAdOx1 nCoV-19 (AZD1222) (Oxford-AstraZeneca; chimpanzee adenoviral vectored) have been approved globally and have been most fr…”
BackgroundMeasure of Value: FDA in the Age of COVID
Beninger, P. R. (2022) · Journal of Regulatory Science · doi:10.21423/jrs-v10i1beninger · Cited by 2
Feng, J., Wang, W.-J., Jin, P., Zheng, H., Jin, L., Xia, X., Zhang, X., Li, Z.-P., Li, J., & Zhu, F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2230760 · Cited by 2
“BNT162b2 and mRNA-1273 elicited excellent shortterm neutralizing antibody responses and protective effectiveness.(6,7) But these mRNA vaccines induced high serum neutralizing antibodies that waned by 3–6 months, with a halflife of 60 d.”
BackgroundShiraishi, M., Narushima, M., Banda, C. H., Mitsui, K., Danno, K., Ishiura, R., Kurita, M., Yuzuriha, S., & Okazaki, M. (2023) · Annals of Vascular Diseases · doi:10.3400/avd.oa.22-00126 · Cited by 2
Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders
Kasai, R., Funato, M., Maruta, K., Yasuda, K., Minatsu, H., Ito, J., & Takahashi, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1103196 · Cited by 2
“The novel coronavirus disease-19 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is on the verge of being endemic globally.”
BackgroundInfluentialBlauvelt, C. A., Pullins, M. J., & Gaw, S. L. (2024) · AJPM Focus · doi:10.1016/j.focus.2024.100303 · Cited by 3
SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies
Raman, R., Patel, K. J., & Ranjan, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-08045-6_7 · Cited by 4
Krintus, M., Piasecki, M., Lackowski, P., Buszko, K., Kubica, A., Kosobucka, A., Michalski, P., Pietrzykowski, Ł., Stolarek, W., Wójcik-Kula, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122125 · Cited by 4
“Encouraging data from two phase III BNT162b2 vaccine efficacy trials and randomized clinical trials demonstrated up to 95% efficacy following a two-dose vaccination regimen [3,4].”
MethodInfluentialTechnologies for Making New Vaccines
Pecetta, S., Ahmed, S., Ellis, R. W., & Rappuoli, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00067-0 · Cited by 2
Luo, C., Chen, H., & Tung, T. (2023) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2023.102538 · Cited by 3
“At this point, a safe and effective preventive vaccine would be considered a useful tool to reduce spread rates and subsequent infection (Polack et al., 2020; Russell and Greenwood, 2021; Palacios et al., 2020).”
BackgroundZhang, G., Kuang, S., & Zhang, X. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2031453 · Cited by 4
Wang, Q., Hu, S., Du, F., Zang, S., Xing, Y., Qu, Z., Zhang, X., Lin, L. K., & Hou, Z. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3940252 · Cited by 2
Frydrysiak-Brzozowska, A., Haor, B., Pluta, A., & Głowacka, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124297 · Cited by 2
“…Control and Prevention (CDC) in the United States, the National Health Service (NHS) in the United Kingdom, and similar institutions in Australia, Japan, and Brazil have consistently demonstrated the effectiveness of vaccination in reducing severe COVID-19 outcomes among older adults [15,16].”
Zarandi, P. K., Zinatizadeh, M. R., Ghiasi, M., Rukerd, M. R. Z., Mirkamali, H., & Shokri, E. (2025) · Health Science Reports · doi:10.1002/hsr2.71405 · Cited by 3
“Pfizer's BNT162b2 and Mod-erna's mRNA ‐ 1273 use lipid nanoparticle (LNP) systems that not only protect the mRNA but also activate innate immune responses by enhancing cytokine production and antigen presentation [136, 137].”
Optimal Vaccination and Treatment Strategies in Reduction of COVID-19 BurdenPreprint
Chhetri, B., Vamsi, D. K. K., Balasubramanian, S., et al. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2102.09802 · Cited by 2
Study of functional lipid nanoparticles for mRNA delivery using new ionizable tocopherol derivatives
Choi, M., Jung, O., Lee, E., & Choi, J. S. (2024) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12909 · Cited by 2
Sallah, H., Cheesman, B. T., Peeler, D. J., Howe, A. M., Shattock, R. J., Coulston, R. J., & Tregoning, J. S. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102585 · Cited by 2
Comparison of two currently available anti-COVID-19 vaccines
Pawliczak, R. (2021) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2021.102554 · Cited by 2
González-Celestino, A., González‐Osorio, Y., García-Iglesias, C., Iñiguez, A. E., Sierra, Á., García, A. R., Trigo-López, J., Planchuelo‐Gómez, Á., Hurtado, M. L., Sierra-Martínez, L., et al. (2023) · Revista de Neurología · doi:10.33588/rn.7710.2023063 · Cited by 2
Nakayama, T., Sekino, H., Aihara, H., & Kino, M. (2022) · Healthcare · doi:10.3390/healthcare10050800 · Cited by 2
Hospital-Based RNA Therapeutics
Damase, T. R., Sukhovershin, R. A., Zhang, M., Kiss, D., & Cooke, J. P. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_4 · Cited by 5
Xu, C., He, Z., Lei, W., Chen, L., Shen, D., Wang, X., Xu, D., Xu, Y. M., & Huang, J. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07808-2 · Cited by 3
COVID-19 Antibodies in Vaccinated Healthcare Workers: The Security Currency
Ammar, A., Shah, J. A., Khan, W., Kumar, R., Shaikh, A. H., Ali, F., Zehra, M., Sial, J. A., Saghir, T., & Rehman, Z. U. (2022) · Cureus · doi:10.7759/cureus.23383 · Cited by 2
“The vaccination strategy for most of the currently approved vaccines is a twostage "prime and boost" strategy with the first dose followed by the second at least three weeks later [5,6].”
BackgroundLeroux‐Roels, I., Coster, I. D., Borobia, A. M., Langley, J. M., Mazarro, D. O., Ruíz‐Antorán, B., Berrè, S., Germain, S., Knauer, C., Koch, S., et al. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2631804 · Cited by 5
Pavlík, T., Jarkovský, J., Šanca, O., Vašáková, M., Dlouhý, P., Černý, V., Štourač, P., Válek, V., & Dušek, L. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae685 · Cited by 3
“Vaccines have been shown to significantly reduce the number of COVID-19–related hospitalizations and deaths before and after the emergence of the SARS-CoV-2 Omicron (B.1.1.529) variant [1–3].”
InfluentialGanasegeran, K., Jamil, M. F. A., Ch’ng, A. S. H., et al. (2024) · GeoJournal · doi:10.1007/s10708-024-11111-9 · Cited by 2
“Although assessments of individual-level data demonstrated the ability of vaccines to decrease severe complications and clinical endpoints (Polack et al., 2020), these evaluations were not powered to offer epidemiological insights.”
COVID-19 Vaccines, What do we know so Far? A Narrative Review
Hamieh, C. (2021) · International Journal of Current Science Research and Review · doi:10.47191/ijcsrr/v4-i5-18 · Cited by 2
“CDC advise people who have received the vaccine to seek medical help if they develop severe headache, new neurologic symptoms, severe abdominal pain, shortness of breath, leg swelling, tiny red spots on the skin (petechiae), or new or easy bruising, within the first 3 weeks ([36]).”
BackgroundMartins‐Filho, P. R., Santana, R. R. R., Cavalcante, T. F., Barboza, W. D. S., de Souza, M. F., Góes, M. A. D. O., Fontes, Â. M. B., da Silva, M. E. L., & Tanajura, D. M. (2022) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2022.110 · Cited by 4
Filchtinski, D., Sundberg, M., Berthold, H., Steller, L., Kayser, J., Holz, S., Hinze, M., Braeutigam, O., Schulte-Pelkum, J., & Fiedler, R. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2022.113258 · Cited by 2
Potential challenges to doctor–patient trust posed by personalized medicine
Cohen, S. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780198863465.003.0012 · Cited by 3
The New Modern Medicine: Disease, Evidence, and Epidemiological Medicine
Fuller, J. (2025) · doi:10.1093/9780190066178.001.0001 · Cited by 7
Thesenpapier 7.0 zur Pandemie durch SARS-CoV-2/Covid-19
al., S. E. (2021) · Monitor Versorgungsforschung · doi:10.24945/mvf.01.21.1866-0533.2283 · Cited by 2
Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual
Kernéis, S., Planas, D., Imbeaud, S., Staropoli, I., Puech, J., Robillard, N., Rodary, J., Bruel, T., Vieillard, T., Schwartz, O., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab369 · Cited by 2
Takano, T., Kumagai, K., Iuchi, H., Terahara, K., Mizuike, A., Sasaki, E., Adachi, Y., Kotaki, R., Moriyama, S., Ota, S., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01441-9 · Cited by 6
Hayashi, T., Sano, K., & Konishi, I. (2024) · Infectious Disease Reports · doi:10.3390/idr16030036 · Cited by 3
“Passive immunization through vaccination is pivotal in shielding the fetus from placental transmission of SARS-CoV-2 [23–25].”
BackgroundTseng, W.-P., Wu, J.-L., Lin, C., Kang, C., Chung, M., Lee, Y.-F., Chen, S., Lu, M., Ko, W., Lee, P., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127383 · Cited by 4
Dentone, C., Fenoglio, D., Ponzano, M., Cerchiaro, M., Altosole, T., Franciotta, D. M., Portunato, F., Mikulska, M., Taramasso, L., Magnasco, L., et al. (2022) · Vaccines · doi:10.3390/vaccines10111784 · Cited by 2
“Fully functional vaccine-elicited early memory CD8+ T cells patrol the periphery for SARS-CoV-2 at least within the first months after vaccination [31,32].”
BackgroundSolaymani–Dodaran, M., Basiri, P., Moradi, M., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02121-z · Cited by 2
“Other vaccine platforms also reported higher rates of adverse reactions [11, 12].”
BackgroundEffects of SARS-CoV-2 Vaccines on Sperm Quality: Systematic Review
Li, G., Zhang, R., Song, B., Wang, C., Shen, Q., He, X., & Cao, Y. (2023) · JMIR Public Health and Surveillance · doi:10.2196/48511 · Cited by 3
COVID-19 mRNA Based Vaccine Immune-Response Assessment for Public Health DecisionPreprint
Segundo, D. S., Comins, A., Lamadrid, P., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3937557 · Cited by 2
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.